# MICRO-X INVESTOR OPEN DAY PRESENTATION RECORDING

**Adelaide, Australia, 10 September 2026:** Australian hi-tech company Micro-X Ltd (ASX:MX1) (Micro-X or the Company), a leader in cold cathode X-ray technology for health and security markets globally, provides an update following its 2026 Investor Open Day held at its Tonsley Innovation Precinct facility in Adelaide on Friday, 4 September 2026.

The materials presented at the Investor Open Day were a reordered version of the presentation released to the ASX on 3 August 2026, and no new material information was disclosed at the event. A recording of the presentations is available at https://youtu.be/6go8pHqVNhg for investors and analysts unable to attend.

The Investor Open Day provided investors and analysts with an update on the strategic reset being implemented from the beginning of FY27 under new leadership. The event included presentations from CEO Dr Brian Gonzales, COO Anthony Skeats and members of the senior leadership team, a tour of Micro-X's vertically integrated design and production facility, and live demonstrations of the updated Rover and Head CT platforms.

Key Investor Open Day Takeaways

- **Refined strategic focus on medical imaging**, with Head CT the Company's primary new product development and value creation opportunity and Rover providing the current commercial revenue base. Security programs continue under existing contracts and through strategic partnerships.
- **Head CT has progressed into human imaging**, with the pilot study commencing at the Royal Melbourne Hospital during the June 2026 quarter. Key priorities are completion of clinical validation, FDA 510(k) submission and the Head CT ambulance trial, demonstrating the potential for CT imaging at the point of care.
- **Rover has been reset to build a scalable, profitable business**, following a 10-week review by revenue growth consultancy Altus Alliance. Changes include a restructured sales team, a revamped CRM, a stronger customer success function, pipeline build across direct and partner channels, and an updated Rover platform targeting lower manufacturing costs and higher margins.
- **Improved financial rigour under new CFO Peter Dickman**, with more than $3M per annum of annualised savings identified, representing approximately 15% of the core operating cost base. The Company's runway has been extended through FY27, supported by $8M of convertible note financing commitments and $8.1M of contracted development receipts expected during FY27.
- **NEX (Nano Electronic X-ray)**, Micro-X's proprietary cold cathode carbon nanotube emitter platform, underpins the Company's strategy. Micro-X was the first to commercialise the technology in a certified medical device, and NEX now supports three CT programs on a single platform: Head CT (in human trials), Full Body CT (funded by US Government agency ARPA-H) and Security CT (for DHS/TSA). More than $90M in government and partnership funding has supported development of the technology to date.

Micro-X CEO Dr Brian Gonzales said:
"It was an honour to welcome our investors to Micro-X and have the opportunity to show them first-hand the technology, products and people behind the Company. I am incredibly excited about the future of Micro-X. We have built a strong technology foundation, we have brilliant people across the Company, and we are now putting in place the commercial focus and restructured sales team needed to turn that foundation into sustainable commercial success. There is a lot of work ahead of us, but I believe we have the technology, the people and the strategy to build a world-leading company."

This ASX Announcement is authorised by Brian Gonzales, CEO of Micro-X.

## About Micro-X

Micro-X Limited is an ASX-listed hi-tech company developing and commercialising innovative medical imaging products for global healthcare markets, together with selected security applications, based on proprietary cold cathode, carbon nanotube (CNT) emitter technology. Electronic control of the emitters enables X-ray products with significant reductions in size, weight and power requirements, supporting greater mobility and ease of use in existing X-ray markets and enabling new security applications. Micro-X has a fully vertically integrated design and production facility in Adelaide, Australia, and a growing technical and commercial team based in Seattle supporting its US business.

Micro-X's strategic focus is the development and commercialisation of medical CT imaging, supported by its established mobile digital radiology business and selected security applications. Its mobile digital radiology products are sold for diagnostic imaging in global healthcare, military and veterinary applications. A miniature brain CT imager for pre-hospital stroke diagnosis in ambulances is being developed with funding from the Australian Government's Medical Research Future Fund and Industry Growth Program. In November 2024, US Government agency ARPA-H contracted Micro-X to develop a full-body CT. In security, Micro-X remains under contract with the US Department of Homeland Security to design a next-generation airport security checkpoint.

For more information visit: www.micro-x.com

## Micro-X and investor enquiries

Brian Gonzales, Chief Executive Officer
Tel: +1 901 313 8667
Email: bgonzales@micro-x.com

Peter Dickman, Chief Financial Officer
Tel: +61 8 7099 3966
Email: pdickman@micro-x.com